Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Blood (2024) 144 (Supplement 1): 685.

https://doi.org/10.1182/blood-2024-194414

Published: 2024

Journal Articles

Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)

Mary Eapen, Joseph Antin, Jakub Tolar, Sally Arai, Mitchell Horwitz, Jainqun Kou, Eric Leifere, John M. McCarty, Ryotaro Nakamura, Michael A. Pulsipher, Mary M. Horowitz, H Joachim Deeg

Blood (2023) 142 (Supplement 1): 235.

https://doi.org/10.1182/blood-2023-178093

Published: 2023

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

Sarah Nikiforow, Mitchell Horwitz, John M. McCarty, Anum Abbas, James M. Coghill, Jenny Stanton, Julie Ma, Spyridoula Vasileiou, Sarah Gilmore, Bhagirathbhai Dholaria, Rabi Hanna, Randy Taplitz, Rajat Bansal

Blood (2023) 142 (Supplement 1): 6889.

https://doi.org/10.1182/blood-2023-189708

Published: 2023

Journal Articles

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Blood (2021) 138 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2021-145527

Published: 2021

Journal Articles

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137677

Published: 2020

Journal Articles

Potential Impact of Sickle Hemoglobin Concentration on Survival Among Patients with Renal Medullary Carcinoma and Sickle Cell Trait

Marcus A. Carden, MD, Jonathan Metts, MD, John M. McCarty, MD, Sarah Mitchell, MD, Bradley Carthon, MD PhD, David A. Siegel, MD, Louis Rapkin, MD, Morgan L. McLemore, MD

Blood (2019) 134 (Supplement_1): 4843.

https://doi.org/10.1182/blood-2019-125088

Published: 2019

Journal Articles

Hematopoietic Cell Transplantation Donor Selection Reimagined: KIR-KIR Ligand Interactions and a Formalized Donor Risk Index Effective at Predicting Survival

Elizabeth Krieger, MD, Urmila Sivagnanaling, Katherine Webb, Dana Broadway, Catherine Roberts, PhD, John M. McCarty, MD, Christina M. Wiedl, DO, Rizwan Romee, MD PhD, Armand Keating, MD, Rehan Qayyum, Amir Ahmed Toor, MBBS

Blood (2019) 134 (Supplement_1): 4616.

https://doi.org/10.1182/blood-2019-129384

Published: 2019

Journal Articles

Peptides Derived from the CMV Proteome Mimic Unique Stem Cell Transplant Recipient Specific Peptides: Possible Role in Eliciting a Pro-Gvh T Cell Response

Charles E. Hall, MS, Max Jameson-Lee, PhD, Abdelrhman Elnasseh, Vishal Koparde, PhD, Allison F. Scalora, MS, Catherine H. Roberts, PhD, Nihar U. Sheth, MS, Myrna G. Serrano, PhD, Daniel Nixon, DO, PhD, Harold M. Chung, MD, Oveimar A. De la Cruz, MD, William B. Clark, MD, John M. McCarty, MD, Gregory A. Buck, PhD, Michael C. Neale, PhD, Amir A. Toor, MD

Blood (2015) 126 (23): 4285.

https://doi.org/10.1182/blood.V126.23.4285.4285

Published: 2015

Journal Articles

The Use of Biomarker Ferritin and Albumin As Well As HCT-CI, but Not PAM, Was Predictive of Suvival, Gvhd and, Relapse in Myeloid Malignancies

Gary Simmons, DO, Allison F. Scalora, MS, Roy T Sabo, PhD, Catherine H. Roberts, PhD, William B. Clark, MD, Harold M. Chung, MD, Amir A. Toor, MD, John M. McCarty, MD

Blood (2015) 126 (23): 5448.

https://doi.org/10.1182/blood.V126.23.5448.5448

Published: 2015

Journal Articles

Lymphocyte Recovery Kinetics in Patients Undergoing Myeloablative Conditioning and Allogeneic Stem Cell Transplantation

David Jared Kobulnicky, MD, Roy T Sabo, PhD, Ali S Shubar Ali, BS, Catherine H. Roberts, PhD, Allison F Scalora, MS, Kristen M Kobulnicky, MS, Shiyu Song, MDPhD, William B. Clark, MD, Harold M. Chung, MD, John M. McCarty, MD, Michael C. Neale, PhD, Amir A. Toor, MD

Blood (2015) 126 (23): 5467.

https://doi.org/10.1182/blood.V126.23.5467.5467

Published: 2015

Journal Articles

A Mathematical Model of Hematopoietic Stem Cell Transplantation and Analysis of the Effect of Drug Treatments on Transplantation in Patients with Lymphoma

Racheal L Cooper, MS, Allison F. Scalora, MS, Elaine Wang, MD, John M. McCarty, MD, Jennifer Anderson, RN, Catherine H. Roberts, PhD, Troy Lund, MD PhD, Amir A. Toor, MD, Angela Reynolds, PhD

Blood (2015) 126 (23): 2376.

https://doi.org/10.1182/blood.V126.23.2376.2376

Published: 2015

Journal Articles

Optimized Cyclophosphamide (CY) Dosing in Combination with Fludarabine, TBI and ATG As Conditioning for Unrelated Donor Bone Marrow Transplantation (BMT) in Severe Aplastic Anemia (SAA): A Phase I/II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Paolo Anderlini, MD, Juan Wu, MS, H. Joachim Deeg, MD, Iris Gersten, MS, Marian Ewell, ScD, Jakub Tolar, MD PhD, Joseph H. Antin, MD, Sally Arai, MD, Mitchell E. Horwitz, MD, John M. McCarty, MD, Ryotaro Nakamura, MD, Michael A. Pulsipher, MD, Roberta H. Adams, MD, Eric Leifer, PhD, Shelly L Carter, ScD, Nancy L DiFronzo, PhD, Mary M. Horowitz, MD MS, Dennis L. Confer, MD, Mary Eapen, MBBS, MS

Blood (2014) 124 (21): 541.

https://doi.org/10.1182/blood.V124.21.541.541

Published: 2014

Journal Articles

Favorable T Cell Reconstitution In Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation with Low-Dose Rabbit Anti-Thymocyte Globulin and Total Body Irradiation

Radhika Thorn, MD, Jeremy Meier, BS, Elaine Wang, MD, Roy T Sabo, PhD, Allison F Scalora, MS, Catherine H Roberts, PhD, Shiyu Song, MD, PhD, Masoud H Manjili, DVM, PhD, William B Clark, MD, John M McCarty, MD, Harold M Chung, MD, Amir A Toor, MD

Blood (2013) 122 (21): 4577.

https://doi.org/10.1182/blood.V122.21.4577.4577

Published: 2013

Journal Articles

Immune Reconstitution In Anti-Thymocyte Globulin Conditioned Unrelated Donor Stem Cell Transplantation

David Jared Kobulnicky, MD, Roy T Sabo, PhD, Allison F Scalora, MS, David Portier, MD, Devon Fletcher, MD, Jeffrey M Tessier, MD, William B Clark, MD, Harold M Chung, MD, John M McCarty, MD, Catherine H Roberts, PhD, Amir A Toor, MD

Blood (2013) 122 (21): 2071.

https://doi.org/10.1182/blood.V122.21.2071.2071

Published: 2013

Journal Articles

Optimizing Outcomes in Multiple Myeloma Using Risk Stratified Allocation to Single Versus Tandem Autologous SCT.

Matthew Risendal, BS, Roy T Sabo, PhD, Allison F Hazlett, MS, Priscilla Mpasi, BS, Joan Bolling, William B Clark, MD, John M McCarty, MD, Harold M Chung, MD, Catherine H Roberts, PhD, Amir A Toor, MD

Blood (2012) 120 (21): 3123.

https://doi.org/10.1182/blood.V120.21.3123.3123

Published: 2012

Journal Articles

Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

Meir Wetzler, MD, Dorothy Watson, B.S., Wendy Stock, MD, Kouros Owzar, PhD, Gregory Koval, B.S., Eva Hoke, John M McCarty, MD, William Blum, MD, Bayard L. Powell, MD, Guido Marcucci, MD, Clara D Bloomfield, Charles Linker, MD, Richard A. Larson, MD

Blood (2012) 120 (21): 816.

https://doi.org/10.1182/blood.V120.21.816.816

Published: 2012

Journal Articles

Favorable Outcomes in Patients with High Donor-Derived T Cell Count Following In Vivo T Cell Depleted Reduced Intensity Allogeneic Stem Cell Transplantation

Amir A Toor, MD, Roy T Sabo, PhD, Harold M Chung, MD, Catherine H Roberts, PhD, Rose H Manjili, BS, Shiyu Song, MD, PhD, David C. Williams, Jr., MD, PhD, William Clark, MD, Masoud H Manjili, DVM, PhD, John M McCarty, MD

Blood (2011) 118 (21): 3043.

https://doi.org/10.1182/blood.V118.21.3043.3043

Published: 2011

Journal Articles

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Jakub Tolar, MD, PhD, H. Joachim Deeg, M.D., Sally Arai, MD, Mitchell Horwitz, MD, Joseph H. Antin, MD, John M. McCarty, MD, Roberta H. Adams, MD, Mary Eapen, MBBS, Marian Ewell, ScD, Eric Leifer, PhD, Iris Gersten, MS, Shelly L Carter, ScD, Mary M. Horowitz, MD, Dennis L Confer, MD, Ryotaro Nakamura, MD, Michael Pulsipher, MD, Nancy L DiFronzo, PhD, Paolo Anderlini, MD

Blood (2011) 118 (21): 3009.

https://doi.org/10.1182/blood.V118.21.3009.3009

Published: 2011

Journal Articles

Adaptive Immunotherapy In Multiple Myeloma: Epigenetic Modification and Immunomodulation by Sequential Azacitidine and Lenalidomide to Generate Cancer Testis Antigen Specific Cellular Immune Response

Amir A Toor, MD, Kyle Payne, BS, Harold M Chung, MD, Catherine H Roberts, PhD, Roy T Sabo, PhD, Maciej Kmieciak, PhD, William Clark, MD, Christy McLaughlin, BS, Angela Buskey, RN, Jennifer Anderson, RN, Rose H Manjili, BS, Susan D. Roseff, MD, John M McCarty, MD, Masoud H Manjili, DVM, PhD

Blood (2011) 118 (21): 2926.

https://doi.org/10.1182/blood.V118.21.2926.2926

Published: 2011

NARROW

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Potential Impact of Sickle Hemoglobin Concentration on Survival Among Patients with Renal Medullary Carcinoma and Sickle Cell Trait

Hematopoietic Cell Transplantation Donor Selection Reimagined: KIR-KIR Ligand Interactions and a Formalized Donor Risk Index Effective at Predicting Survival

Peptides Derived from the CMV Proteome Mimic Unique Stem Cell Transplant Recipient Specific Peptides: Possible Role in Eliciting a Pro-Gvh T Cell Response

The Use of Biomarker Ferritin and Albumin As Well As HCT-CI, but Not PAM, Was Predictive of Suvival, Gvhd and, Relapse in Myeloid Malignancies

Lymphocyte Recovery Kinetics in Patients Undergoing Myeloablative Conditioning and Allogeneic Stem Cell Transplantation

A Mathematical Model of Hematopoietic Stem Cell Transplantation and Analysis of the Effect of Drug Treatments on Transplantation in Patients with Lymphoma

Optimized Cyclophosphamide (CY) Dosing in Combination with Fludarabine, TBI and ATG As Conditioning for Unrelated Donor Bone Marrow Transplantation (BMT) in Severe Aplastic Anemia (SAA): A Phase I/II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Favorable T Cell Reconstitution In Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation with Low-Dose Rabbit Anti-Thymocyte Globulin and Total Body Irradiation

Immune Reconstitution In Anti-Thymocyte Globulin Conditioned Unrelated Donor Stem Cell Transplantation

Optimizing Outcomes in Multiple Myeloma Using Risk Stratified Allocation to Single Versus Tandem Autologous SCT.

Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

Favorable Outcomes in Patients with High Donor-Derived T Cell Count Following In Vivo T Cell Depleted Reduced Intensity Allogeneic Stem Cell Transplantation

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Adaptive Immunotherapy In Multiple Myeloma: Epigenetic Modification and Immunomodulation by Sequential Azacitidine and Lenalidomide to Generate Cancer Testis Antigen Specific Cellular Immune Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only